Skip to Main Content

Author Details

Hira Rizvi
Druckenmiler Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center
1978
65
35
PMIDPaper TitleJournal TitlePublished Year
36574773The ectonucleotidase CD39 identifies tumor-reactive CD8<sup>+</sup> T cells predictive of immune checkpoint blockade efficacy in human lung cancer.Immunity2023
37487667Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study.J Immunother Cancer2023
37589215Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.Oncologist2023
37024582Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.Nat Genet2023
37247843Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC.J Thorac Oncol2023
37001526Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade.Cancer Cell2023
37432985Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.Clin Cancer Res2023
37223888The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non-Small Cell Lung Cancer.Clin Cancer Res2023
34740862Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.J Thorac Oncol2022
35708671Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.JAMA Oncol2022
35477182Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer.Cancer Epidemiol Biomarkers Prev2022
35767426Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer.Clin Cancer Res2022
35533926Deciphering radiological stable disease to immune checkpoint inhibitors.Ann Oncol2022
36074020Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers.Cancer Res2022
36048199Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort.Cancer Discov2022
35192403A Scalable Quality Assurance Process for Curating Oncology Electronic Health Records: The Project GENIE Biopharma Collaborative Approach.JCO Clin Cancer Inform2022
35121086A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry.J Thorac Oncol2022
34734967Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies.JAMA Oncol2022
32958579Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade.Cancer Discov2021
33685865Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with <i>EGFR</i> Exon 20 Insertions.Clin Cancer Res2021
33568350Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade.J Immunother Cancer2021
33558425Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer.Clin Cancer Res2021
34536733Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer.Lung Cancer2021
34215621Quantitative <i>In Vivo</i> Analyses Reveal a Complex Pharmacogenomic Landscape in Lung Adenocarcinoma.Cancer Res2021
34244291Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer.Clin Cancer Res2021
34265432Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events.J Thorac Oncol2021
34115989Tim-4[+] cavity-resident macrophages impair anti-tumor CD8[+] T cell immunity.Cancer Cell2021
34332931The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study.Lancet Digit Health2021
34022698Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics.Eur J Cancer2021
33355651A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma.JAMA Surg2021
32398243Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers.Cancer Discov2020
32046999Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC.Clin Cancer Res2020
31911548Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in <i>EGFR</i>-Mutant Lung Cancer.Clin Cancer Res2020
33007267Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.Cell2020
32709715The Genomic Landscape of <i>SMARCA4</i> Alterations and Associations with Outcomes in Patients with Lung Cancer.Clin Cancer Res2020
32905464COVID-19 Presenting as Severe Rhabdomyolysis With Normal Renal Function.Cureus2020
32753547Outcomes to first-line pembrolizumab in patients with PD-L1-high (â¿¥50%) non-small cell lung cancer and a poor performance status.J Immunother Cancer2020
32178965Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.Ann Oncol2020
32463456Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.JAMA Oncol2020
32561401COVID-19 in patients with lung cancer.Ann Oncol2020
30847464Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.Ann Oncol2019
31675272Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade.J Clin Oncol2019
31832578Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer.JCO Precis Oncol2019
30045933Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <i>EGFR</i>-Mutant Lung Cancers.Clin Cancer Res2019
31435660Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.Ann Oncol2019
31228622Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.J Thorac Oncol2019
31086949EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.Ann Oncol2019
29097494Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.Science2018
29915805Next-generation sequencing based detection of germline and somatic alterations in a patient with four metachronous primary tumors.Gynecol Oncol Rep2018
29991499Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC.Cancer Immunol Res2018
  • 1 - 50 of 65

Recommended Authors

James Carroll
David Geffen School of Medicine at the University of California los angeles
Career Start Year 2017
Number of shared co-authors 3
Daniel Kazdal
Institut fur Pathologie, Universitatsklinikum Heidelberg
Career Start Year 2016
Number of shared co-authors 1
Daniel W Kelly
Memorial Sloan Kettering Cancer Center
Career Start Year 2016
Number of shared co-authors 8
Mark Lee
Memorial Sloan Kettering Cancer Center (MSKCC)
Career Start Year 2015
Number of shared co-authors 4
Amy L Cummings
university of california los angeles School of Medicine
Career Start Year 2014
Number of shared co-authors 5
Jyoti Malhotra
Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School
Career Start Year 2012
Number of shared co-authors 4
Yang Shao
Nanjing Geneseeq Technology Inc.
Career Start Year 2012
Number of shared co-authors 1
Siddhartha Devarakonda
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 2011
Number of shared co-authors 5
Gareth Rivalland
Auckland City Hospital
Career Start Year 2010
Number of shared co-authors 0
Saiama N Waqar
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 2009
Number of shared co-authors 6
Vibha Raghavan
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2009
Number of shared co-authors 0
Caroline E McCoach
UCSF Helen Diller Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 5
Chen Hu
Johns Hopkins University School of Medicine
Career Start Year 2009
Number of shared co-authors 4
Ashiq Masood
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Career Start Year 2008
Number of shared co-authors 0
Gideon M Blumenthal
Oncology Center of Excellence
Career Start Year 2008
Number of shared co-authors 6
Bhumsuk Keam
Seoul National University Hospital
Career Start Year 2006
Number of shared co-authors 0
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 7
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 10
Lecia V Sequist
Massachusetts General Hospital Cancer Center, Harvard Medical School
Career Start Year 2003
Number of shared co-authors 19
Fiona Blackhall
The University of Manchester
Career Start Year 2000
Number of shared co-authors 6
Daniel Morgensztern
Washington University School of Medicine
Career Start Year 2000
Number of shared co-authors 7
Benjamin Solomon
Peter MacCallum Cancer Centre
Career Start Year 2000
Number of shared co-authors 10
Collin M Blakely
University of California san francisco
Career Start Year 1998
Number of shared co-authors 11
Anthony J Iafrate
Massachusetts General Hospital
Career Start Year 1997
Number of shared co-authors 21
Peter S Hammerman
Novartis Institutes for BioMedical Research
Career Start Year 1996
Number of shared co-authors 12
Cheryl Ho
University of British Columbia
Career Start Year 1995
Number of shared co-authors 1
Jorge Nieva
Norris Comprehensive Cancer Center, University of Southern California
Career Start Year 1995
Number of shared co-authors 1
Timothy A Chan
Cleveland Clinic.
Career Start Year 1994
Number of shared co-authors 23
Jonathan W Goldman
David Geffen School of Medicine at university of california los angeles
Career Start Year 1991
Number of shared co-authors 10
Ramaswamy Govindan
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 1981
Number of shared co-authors 12

Collaborators

Gregory J Riely
Memorial Sloan Kettering Cancer Center
Co-authored papers 24
Charles M Rudin
Memorial Sloan Kettering Cancer Center
Co-authored papers 23
Marc Ladanyi
Memorial Sloan Kettering Cancer Center
Co-authored papers 18
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Co-authored papers 8
Ronglai Shen
Co-authored papers 7
Francisco Vega
The University of Texas MD Anderson Cancer Center
Co-authored papers 6
Chaitanya Bandlamudi
Co-authored papers 6
Michael F Berger
Co-authored papers 5
Pasi A J??nne
Dana-Farber Cancer Institute
Co-authored papers 4
Subba R Digumarthy
Massachusetts General Hospital, USA Harvard Medical School
Co-authored papers 4
Barry S Taylor
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Katherine S Panageas
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Jessica A Lavery
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Andrew Chow
Co-authored papers 4
Jianjun Zhang
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Andrew D Cherniack
Dana-Farber Cancer Institute
Co-authored papers 3
Michele L LeNoue-Newton
Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center
Co-authored papers 3
Deborah Schrag
Memorial-Sloan Kettering Cancer Center
Co-authored papers 3
Elisa de Stanchina
Co-authored papers 3
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 3
Jeremy L Warner
Vanderbilt University Medical Center
Co-authored papers 3
Benjamin D Greenbaum
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Ben Ho Park
Vanderbilt University Medical Center
Co-authored papers 2
Aadel A Chaudhuri
Co-authored papers 2
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 2
Gad Getz
Broad Institute of the Massachusetts Institute of Technology and Harvard
Co-authored papers 2
Michael Y Tolstorukov
Dana-Farber Cancer Institute
Co-authored papers 2
Arvind Ravi
Co-authored papers 2
Travis J Hollmann
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Xihong Lin
Harvard T.H. Chan School of Public Health
Co-authored papers 2
Release 1.2